Neos Therapeutics: FDA approves Adzenys ER Extended-Release Oral Suspension
Neos Therapeutics announced that the U.S. FDA has approved Adzenys ER Extended-Release Oral Suspension. Neos Therapeutics is the only company to offer both branded amphetamine and methylphenidate products in extended-release dosage forms. Once commercially available, Adzenys ER oral suspension will be the third Neos extended release product for the treatment of Attention Deficit Hyperactivity Disorder. The other Neos extended-release products for the treatment of ADHD are Adzenys XR-ODT Extended-Release Orally Disintegrating Tablets and Cotempla XR-ODT Extended-Release Orally Disintegrating Tablets. Adzenys ER will be commercially available in early 2018.